Clozapine-induced gastroesophageal rumination in 22q11.2 Deletion Syndrome. A case report on gastroesophageal side effects management without renouncing clozapine's effectiveness
- PMID: 34084508
- PMCID: PMC8142464
- DOI: 10.1002/ccr3.4134
Clozapine-induced gastroesophageal rumination in 22q11.2 Deletion Syndrome. A case report on gastroesophageal side effects management without renouncing clozapine's effectiveness
Abstract
Despite entailing more severe and uncommon side effects in 22q11.2DS compared to idiopathic schizophrenia, we strongly believe that clozapine should continue to be considered the gold standard for all treatment-resistant schizophrenia, even in 22qDS.
Keywords: genetics; pharmacology; psychiatry.
© 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
Conflict of interest statement
None declared.
References
-
- Botto LD, May K, Fernhoff PM, et al. A population‐based study of the 22q11.2 Deletion: Phenotype, incidence, and contribution to major birth defects in the population. Pediatrics. 2003;112:101‐107. - PubMed
-
- Murphy KC. Schizophrenia and velo‐cardio‐facial syndrome. Lancet. 2002;359:426‐430. - PubMed
-
- Verhoeven WMA, Egger JIM. Atypical antipsychotics and relapsing psychoses in 22q11.2 deletion syndrome: A long‐term evaluation of 28 patients. Pharmacopsychiatry. 2015;48:104‐110. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
